Sheila Gujrathi Buys 130,000 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Director Sheila Gujrathi purchased 130,000 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was bought at an average price of $2.31 per share, with a total value of $300,300.00. Following the acquisition, the director now owns 130,000 shares in the company, valued at $300,300. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Ventyx Biosciences Stock Performance

Shares of VTYX stock opened at $2.33 on Friday. The stock has a market capitalization of $164.76 million, a price-to-earnings ratio of -0.99 and a beta of 0.48. Ventyx Biosciences, Inc. has a one year low of $1.67 and a one year high of $11.48. The company’s 50-day simple moving average is $2.29 and its 200-day simple moving average is $2.33.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Oppenheimer restated an “outperform” rating and issued a $9.00 target price (down from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. HC Wainwright reissued a “neutral” rating and issued a $6.00 price objective on shares of Ventyx Biosciences in a research report on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Ventyx Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Institutional Investors Weigh In On Ventyx Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in VTYX. Palumbo Wealth Management LLC acquired a new stake in shares of Ventyx Biosciences during the third quarter worth $26,000. China Universal Asset Management Co. Ltd. boosted its stake in Ventyx Biosciences by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after acquiring an additional 5,310 shares during the period. SG Americas Securities LLC acquired a new position in Ventyx Biosciences in the second quarter valued at approximately $32,000. Intech Investment Management LLC bought a new position in shares of Ventyx Biosciences during the third quarter valued at approximately $42,000. Finally, The Manufacturers Life Insurance Company raised its position in shares of Ventyx Biosciences by 41.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after purchasing an additional 7,096 shares during the period. 97.88% of the stock is owned by institutional investors and hedge funds.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.